4E2 Stock Chart & Stats
€5.75
-€0.01(-2.14%)
At close: 4:00 PM EST
€5.75
-€0.01(-2.14%)
Day’s Range― - ―
52-Week Range€0.47 - €6.50
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€460.63M
Enterprise Value€368.75
Total Cash (Recent Filing)€233.96M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding104,890,220
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.59Price Target Upside118.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase 2 Efficacy And FDA-aligned Phase 3 PathHigh and durable Phase 2 CR rates combined with explicit FDA alignment for two registrational pathways materially reduce regulatory uncertainty and increase the probability that Phase 3 success could translate into an approvable label and meaningful commercial opportunity across large patient pools.
Debt-free Balance Sheet And $234M Cash Runway Through 2029A debt-free capital structure and a freshly strengthened cash position provide durable financial flexibility to execute planned Phase 3 and PoC programs without near-term debt servicing pressures, reducing short-term financing risk and allowing management to focus resources on clinical execution.
Operational Differentiation And IP FilingA ready-to-use, short in-office administration lowers commercialization friction versus complex therapies and supports outpatient adoption. Combined with a provisional patent application that could extend exclusivity if issued, this creates structural commercial and partnering advantages if clinical outcomes are confirmed.
Bears Say
Pre-revenue Status With Persistent Cash BurnRelmada remains pre-revenue and consistently cash-negative, meaning long-term value depends entirely on clinical and regulatory success. Persistent operating and free cash flow deficits increase reliance on external capital, constrain reinvestment flexibility, and amplify dilution or financing timing risks.
Execution And Enrollment Risk In Phase 3Heterogeneous prior-treatment allowances and real-world enrollment variability can dilute observed treatment effects, complicate regulatory interpretation, and lengthen timelines. These structural trial-design and operational execution risks directly affect probability of approval and commercial predictability.
Dilution Risk And Rising Operating ExpensesA recent authorized-share increase and a large PIPE already used to bolster cash, together with materially higher G&A driven by compensation, indicate elevated funding needs and structural upward pressure on fixed costs, making future equity issuance and shareholder dilution more likely.
Relmada Therapeutics News
4E2 FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was €0.47 and its highest was €6.50 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is €460.63M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 12 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on May 12, 2026. The company reported -€0.193 earnings per share for the quarter, missing the consensus estimate of -€0.176 by -€0.018.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 104,890,220 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -€0.193 in its last earnings report, missing expectations of -€0.176. Following the earnings report the stock price went up 7.5%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:4E2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.59 (118.94% Upside)
€12.59 (118.94% Upside)
Blogger Sentiment
Bullish
DE:4E2 Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
623.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
750.32%
Trailing 12-Months
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
4E2 Stock 12 Month Forecast
Average Price Target
€12.59
▲(118.94% Upside)